Home / CCL22/MDC / Human CCL22/MDC Antibody

Human CCL22/MDC Antibody

Catalog #: MAB336
15 Citations 2 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB336-SP
MAB336-500
MAB336-100
Chemotaxis Induced by CCL22/MDC and Neutralization by Human CCL22/MDC Antibody.
7 Images
Product Details
Citations (15)
FAQs
Supplemental Products
Reviews (2)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CCL22/MDC Antibody Summary

Species Reactivity
Human
Specificity
Detects human CCL22/MDC in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant mouse CCL17, recombinant human (rh) CCL17, or rhCCL21 is observed.
Source
Monoclonal Mouse IgG2B Clone # 57226
Purification
Protein A or G purified from ascites
Immunogen
E. coli-derived recombinant human CCL22/MDC
Gly25-Gln93
Accession # O00626.1
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human CCL22/MDC (Catalog # 336-MD)

Human CCL22/MDC Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human CCL22/MDC Biotinylated Antibody (Catalog # BAF336)

Standard: Recombinant Human CCL22/MDC Protein (Catalog # 336-MD)

Neutralization
Measured by its ability to neutralize CCL22/MDC-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR4. The Neutralization Dose (ND50) is typically 0.6-3.0 µg/mL in the presence of 10 ng/mL Recombinant Human CCL22/MDC.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Chemotaxis Induced by CCL22/MDC and Neutralization by Human CCL22/MDC Antibody. View Larger

Chemotaxis Induced by CCL22/MDC and Neutralization by Human CCL22/MDC Antibody. Recombinant Human CCL22/MDC (Catalog # 336-MD) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL22/MDC (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL22/MDC Monoclonal Antibody (Catalog # MAB336). The ND50 is typically 0.6-3.0 µg/mL.

Western Blot Detection of Human CCL22/MDC by Western Blot View Larger

Detection of Human CCL22/MDC by Western Blot MiR‐23a inhibitor reversed p65 inhibition effects on HBV‐positive xenograft tumor growth. A, Xenografted tumors were harvested after different treatments. B and C, p65 inhibitor treatment significantly retarded tumor growth and miR‐23a inhibitor promoted tumor growth as indicated by the tumor weight and size. The therapeutic effects of p65 inhibitor were abolished by cotreatment with miR‐23a inhibitor. D, CCL22 protein levels from each group were detected by western blotting. E, Statistical results in D. p65 inhibitor led to reduction of CCL22 protein level but miR‐23a inhibitor increased CCL22 level in tumor tissues. F, p65 inhibitor led to reduction of CCL22 mRNA level but miR‐23a inhibitor increased CCL22 mRNA level in tumor tissues. MiR‐23a inhibitor reversed p65 inhibition effects on CCL22 level in tumor tissues. Error bars represented mean ± SD. *P < .05 and **P < .01 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31769216), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human CCL22/MDC by Western Blot View Larger

Detection of Human CCL22/MDC by Western Blot MiR‐23a, p‐p65, p65, and CCL22 levels were dysregulated in HCC cell lines. A, RT‐qPCR revealed that miR‐23a expression was lowest in the HBV‐positive HepG2.2.15 cell line. B, Highest mRNA level of CCL22 was observed in HepG2.2.15. C, Protein levels of p‐p65, p65, and CCL22 in three cell lines were determined by Western blotting. D, The gray scale analysis of p‐p65, p65, CCL22 and ratio of p‐p65/p65 in three cell lines. Expression of CCL22, p‐p65, and p65 were higher in HBV+ HepG2.2.15 cells than their parental HBV‐ HepG2 cells and normal WRL68 cells. Error bars represented mean ± SD. **P < .01 and *P < .05 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31769216), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human CCL22/MDC by Western Blot View Larger

Detection of Human CCL22/MDC by Western Blot MiR‐23a inhibited Tregs migration by directly targeting CCL22. A, CCL22 3′UTR contains a putative miR‐23a‐binding site. B, MiR‐23a mimics significantly reduced the luciferase activity tagged with wide type of CCL22 3′UTR. Mutagenesis in the miR‐23a‐binding site abolished the inhibitory actions. C, Transfection of miR‐23a mimics efficiently increased miR‐23a level in both cell lines. D, The effects of miR‐23a overexpression on p‐p65, p65, and CCL22 protein levels in HepG2 and HepG2.2.15 cells were assessed by western blotting. E, The gray scale analysis of p‐p65, p65, CCL22 after miR‐23a overexpression. MiR‐23a mimics transfection did not alter the expression of p65 and its phosphorylation but CCL22 was significantly reduced by miR‐23a mimics. F, MiR‐23a mimics significantly reduced CCL22 mRNA level. G, Overexpression of miR‐23a was sufficient to attenuate Tregs transmigration in both cell lines. Error bars represented mean ± SD. *P < .05, **P < .01, and ***P < .001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31769216), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human CCL22/MDC by Western Blot View Larger

Detection of Human CCL22/MDC by Western Blot Lower miR‐23a expression was correlated with higher level of CCL22 expression and intratumoral Treg recruitment in HBV‐positive HCC. A, HBV infection was associated with patient survival rate of HCC. Patients carrying HBV (n = 30) had significantly poorer prognosis than HBV‐ patients (n = 30). B, HBV‐ tissues (n = 30) and HBV+ tissues (n = 30) expressed significantly lower level of miR‐23a. C, HBV− tissues and HBV+ tissues expressed significantly higher mRNA level of CCL22. D, HBV‐ tissues and HBV+ tissues expressed significantly higher mRNA level of Foxp3. E, The protein levels of CCL22, Foxp3, p‐p65, and p65 in normal control, HBV‐ and HBV+ tumor tissues were evaluated by western blotting. F, The gray scale analysis of CCL22, Foxp3, p‐p65, and p65 in normal control, HBV− and HBV+ tumor tissues. In ascending order: normal < HBV− < HBV+. G, Foxp3 signals (red) were colocalized with CD4 (green) signals in tissues. The ratios of Foxp3+CD4+ cells were gradually increased from normal, HBV− HCC to HBV+ HCC tissues. H. MiR‐23a level was inversely correlated with CCL22 expression in HCC tissues, but not in normal control. I. MiR‐23a level was inversely correlated with Foxp3 expression in HCC tissues, but not in normal control. Error bars represented mean ± SD. **P < .01 and *P < .05. HBV+, HCC tissues with HBV infection. HBV−, HCC tissues without HBV infection. Normal, normal liver samples Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31769216), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human CCL22/MDC by Western Blot View Larger

Detection of Human CCL22/MDC by Western Blot MiR‐23a inhibitor reversed p65 inhibition effects on CCL22 and Tregs recruitment. A, MiR‐23a inhibitor reversed p65 inhibition effects on miR‐23a level. B, The effects of miR‐23a inhibition and p65 inhibitor treatment on p‐p65, p65, and CCL22 protein levels in HepG2 and HepG2.2.15 cells were assessed by western blotting. C, The gray scale analysis of p‐p65, p65, CCL22. MiR‐23a inhibitor reversed p65 inhibition effects on CCL22 protein level but had no effects on p‐p65 and p65. D, MiR‐23a inhibitor reversed p65 inhibition effects on CCL22 mRNA level. E, MiR‐23a inhibitor reversed p65 inhibition effects on Tregs recruitment. F, CCL22 neutralizing antibody reversed miR‐23a inhibitor‐mediated Tregs migration. Error bars represented mean ± SD. *P < .05, **P < .01, and ***P < .001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31769216), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human CCL22/MDC by Western Blot View Larger

Detection of Human CCL22/MDC by Western Blot p65 promoted Tregs recruitment via directly modulating miR‐23a. A, A p65‐binding site could be found in miR‐23a promoter region. B, Overexpression of p65 significantly reduced the luciferase activity driven by miR‐23a promoter. Mutagenesis in the p65‐binding site released such repression. C, ChIP assay confirmed that p65 could bind to the promoter region of miR‐23a. D, p65 inhibition upregulated miR‐23a level. E, p65 inhibitor significantly reduced the p‐p65, p65, and CCL22 protein levels in HepG2 and HepG2.2.15 cells. F, The gray scale analysis of p‐p65, p65, CCL22 after p65 inhibitor treatment. G, p65 inhibition dampened CCL22 mRNA level. H, CD4+CD25+ Foxp3+ human Tregs were identified. I, HBV+ HepG2.2.15 cells caused more Tregs to migrate through transwell membrane than HBV− HpeG2 cells. Pretreatment with p65 inhibitor attenuated Tregs transmigration in both cell lines. Error bars represented mean ± SD. *P < .05, **P < .01, and ***P < .001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31769216), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL22/MDC

CCL22, also named stimulated T cell chemotactic protein (STCP-1) and MDC, is a CC chemokine initially isolated from clones of monocyte-derived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL-2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocyte-derived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV-1 isolates and the T cell line-adapted isolate HIV-1IIIB, has been identified as CCL22. Based on amino-terminal sequence analysis, the major CD8+ T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.

References
  1. Godiska, R. et al. (1997) J. Exp. Med. 185:1595.
  2. Chang, M-S. et al. (1997) J. Biol. Chem. 272:25229.
  3. Pal, R. et al. (1997) Science 278:5338.
Entrez Gene IDs
6367 (Human); 20299 (Mouse)
Alternate Names
A-152E5.1; ABCD-1; CC chemokine STCP-1; C-C motif chemokine 22; CCL22; chemokine (C-C motif) ligand 22; DC/B-CK; Macrophage-derived chemokine; MDC; MDCStimulated T-cell chemotactic protein 1; MGC34554; SCYA22MDC(1-69); small inducible cytokine A22; small inducible cytokine subfamily A (Cys-Cys), member 22; Small-inducible cytokine A22; STCP-1; stimulated T cell chemotactic protein 1

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human CCL22/MDC Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Pathogen Evasion of Chemokine Response Through Suppression of CXCL10
    Authors: Alejandro L. Antonia, Kyle D. Gibbs, Esme D. Trahair, Kelly J. Pittman, Amelia T. Martin, Benjamin H. Schott et al.
    Frontiers in Cellular and Infection Microbiology
  2. Recruitment and significance of Th22 cells and Th17 cells in malignant ascites
    Authors: XW Yang, HX Jiang, R Lei, WS Lu, SH Tan, SY Qin
    Oncol Lett, 2018-08-16;16(4):5389-5397.
  3. Aflatoxin B1 and Epstein-Barr virus-induced CCL22 expression stimulates B cell infection
    Authors: Maroui, MA;Odongo, GA;Mundo, L;Manara, F;Mure, F;Fusil, F;Jay, A;Gheit, T;Michailidis, TM;Ferrara, D;Leoncini, L;Murray, P;Manet, E;Ohlmann, T;De Boevre, M;De Saeger, S;Cosset, FL;Lazzi, S;Accardi, R;Herceg, Z;Gruffat, H;Khoueiry, R;
    Proceedings of the National Academy of Sciences of the United States of America
    Species: Human, Transgenic Mouse
    Sample Types: Cell Culture Supernates, In Vivo
    Applications: Western Blot, Neutralization
  4. L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma
    Authors: Xuan Zhao, Shasha Liu, Xinfeng Chen, Jianyi Zhao, Feng Li, Qitai Zhao et al.
    Cancer Biology and Medicine
  5. Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
    Authors: C Kötting, L Hofmann, R Lotfi, D Engelhardt, S Laban, PJ Schuler, TK Hoffmann, C Brunner, MN Theodoraki
    Cancers, 2021-03-16;13(6):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Capture
  6. p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma
    Authors: ZQ Li, HY Wang, QL Zeng, JY Yan, YS Hu, H Li, ZJ Yu
    Cancer Med, 2019-11-25;0(0):.
    Species: Human
    Sample Types: Protein
    Applications: Western Blot
  7. CCL22 is a biomarker of cartilage injury and plays a functional role in chondrocyte apoptosis
    Authors: G Ren, JL Whittaker, C Leonard, D De Rantere, DSJ Pang, P Salo, M Fritzler, M Kapoor, APJ de Koning, JL Jaremko, CA Emery, RJ Krawetz
    Cytokine, 2019-01-07;115(0):32-44.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  8. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver.
    Authors: Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH
    J. Immunol., 2010-02-17;184(6):2886-98.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  9. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.
    Authors: Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H
    Int. J. Cancer, 2008-05-15;122(10):2286-93.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.
    Authors: Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, Fritz B, Schwarz A, Suri-Payer E, Hensel M, Wildemann B
    Blood, 2007-10-29;111(2):761-6.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  11. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha.
    Authors: Liu LY, Bates ME, Jarjour NN, Busse WW, Bertics PJ, Kelly EA
    J. Immunol., 2007-10-01;179(7):4840-8.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  12. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Authors: Curiel, Tyler J, Coukos, George, Zou, Linhua, Alvarez, Xavier, Cheng, Pui, Mottram, Peter, Evdemon-Hogan, Melina, Conejo-Garcia, Jose R, Zhang, Lin, Burow, Matthew, Zhu, Yun, Wei, Shuang, Kryczek, Ilona, Daniel, Ben, Gordon, Alan, Myers, Leann, Lackner, Andrew, Disis, Mary L, Knutson, Keith L, Chen, Lieping, Zou, Weiping
    Nat Med, 2004-08-22;10(9):942-9.
    Species: Human, Xenograft
    Sample Types: In Vivo, Whole Cells
    Applications: Neutralization
  13. Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma.
    Authors: Liu L, Jarjour NN, Busse WW, Kelly EA
    Am. J. Respir. Crit. Care Med., 2004-03-04;169(10):1118-24.
    Species: Human
    Sample Types: BALF
    Applications: ELISA Development
  14. CCR4 blockade does not inhibit allergic airways inflammation.
    Authors: Conroy DM, Jopling LA, Lloyd CM, Hodge MR, Andrew DP, Williams TJ, Pease JE, Sabroe I
    J. Leukoc. Biol., 2003-07-15;74(4):558-63.
    Species: Guinea Pig
    Sample Types: BALF
    Applications: ELISA Development
  15. Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin
    Authors: SH Omland, EE Wettergren, S Mollerup, M Asplund, T Mourier, AJ Hansen, R Gniadecki
    BMC Cancer, 2017-10-07;17(1):675.

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human CCL22/MDC Antibody

Average Rating: 4 (Based on 2 Reviews)

5 Star
50%
4 Star
0%
3 Star
50%
2 Star
0%
1 Star
0%

Have you used Human CCL22/MDC Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human CCL22/MDC Antibody
By Anonymous on 11/08/2021
Application: WB Sample Tested: T cells Species: Human
Western Blot Human CCL22/MDC Antibody MAB336
Human CCL22/MDC Antibody
By Anonymous on 06/09/2020
Application: ELISA Sample Tested: Serum and Plasma Species: Human

We used this antibody in an in-house ELISA along with pAb (AF336) and protein (336-MD-025) to detect CCL22 in human serum and plasma. This combination could detect CCL18 in human serum and plasma.

ELISA Human CCL22/MDC Antibody MAB336